Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer

被引:10
|
作者
Hanson, Erik D. [1 ,2 ]
Alzer, Mohamdod [1 ]
Carver, Jackson [1 ]
Stopforth, Cameron K. [1 ]
Lucas, Alexander R. [3 ,4 ]
Whang, Young E. [2 ,5 ]
Milowsky, Matthew, I [2 ,5 ]
Bartlett, David B. [6 ,7 ]
Harrison, Michael R. [6 ]
Bitting, Rhonda L. [3 ]
Deal, Allison M. [2 ]
Stoner, Lee [1 ]
Hackney, A. C. [1 ,8 ]
Battaglini, Claudio L. [1 ,2 ]
机构
[1] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[3] Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC USA
[4] Virginia Commonwealth Univ, Dept Hlth Behav & Policy, Richmond, VA USA
[5] Univ N Carolina, Dept Med, Div Oncol, Chapel Hill, NC USA
[6] Duke Univ, Duke Canc Inst, Div Med Oncol, Durham, NC USA
[7] Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Guildford, Surrey, England
[8] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC USA
关键词
ANDROGEN-DEPRIVATION THERAPY; QUALITY-OF-LIFE; PHYSICAL FUNCTION; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; CLINICAL-TRIAL; STRENGTH; ENZALUTAMIDE; ABIRATERONE; PROGRAM;
D O I
10.1038/s41391-022-00523-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions. Purpose To determine the feasibility of a home-based exercise intervention in men with metastatic castration-resistant prostate cancer (mCRPC). Methods mCRPC patients on androgen receptor signaling inhibitors (ARSI) were prescribed a 12-week, home-based exercise intervention using resistance bands and walking. Feasibility was assessed using recruitment, retention, adherence, and outcome capture. Physiological changes and patient reported outcomes were assessed before and after the intervention. Results Of the 62 referrals, 47 were eligible with 22 men performing baseline testing (47% recruitment rate) and 16 completing the intervention (73% retention). Task completion was >86% for all physiological tests. Walking adherence was 80% and resistance training was 63%, the latter falling short of the study target (75%). Training increased thigh muscle cross-sectional area by 22%, time to exhaustion by 19% (both p < 0.05) and peak oxygen uptake by 6% (p = 0.057). Improvements in short physical performance battery scores and 400 m walk demonstrated moderate effect sizes that did not reach significance. Conclusions Home-based exercise is feasible during ARSI treatment for mCRPC. Greater endurance capacity and localized hypertrophy appear as the primary improvements following training. These preliminary findings suggest home-based training may increase exercise accessibility, with important lessons that will inform subsequent trials investigating the efficacy of home-based exercise interventions during mCRPC.
引用
收藏
页码:302 / 308
页数:7
相关论文
共 50 条
  • [21] The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
    Buonerba, Carlo
    Sonpavde, Guru
    Vitrone, Francesca
    Bosso, Davide
    Puglia, Livio
    Izzo, Michela
    Iaccarino, Simona
    Scafuri, Luca
    Muratore, Margherita
    Foschini, Francesca
    Mucci, Brigitta
    Tortora, Vincenzo
    Pagliuca, Martina
    Ribera, Dario
    Riccio, Vittorio
    Morra, Rocco
    Mosca, Mirta
    Cesarano, Nicola
    Di Costanzo, Ileana
    De Placido, Sabino
    Di Lorenzo, Giuseppe
    JOURNAL OF CANCER, 2017, 8 (14): : 2663 - 2668
  • [22] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [23] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
  • [24] Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer
    Lorente, David
    Fizazi, Karim
    Sweeney, Christopher
    de Bono, Johann S.
    EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 488 - 498
  • [25] The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer
    Kim, Valerie S.
    Yang, Helen
    Timilshina, Narhari
    Breunis, Henriette
    Emmenegger, Urban
    Gregg, Richard
    Hansen, Aaron R.
    Tomlinson, George
    Alibhai, Shabbir M. H.
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
  • [26] Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations
    Tsai, Alexander K.
    Kagalwalla, Sana
    Langer, Jenna
    Le-Kumar, Thuy
    Le-Kumar, Vikas
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (1-2) : 51 - 62
  • [27] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [28] New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
    Conteduca, Vincenza
    Mosca, Alessandra
    Brighi, Nicole
    de Giorgi, Ugo
    Rescigno, Pasquale
    CELLS, 2021, 10 (01) : 1 - 13
  • [29] Advances in systemic therapies for metastatic castration-resistant prostate cancer
    Pant, Manish K.
    Abughaban, Ahmed
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (14) : 2213 - 2226
  • [30] Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study
    Maughan, Benjamin L.
    Luber, Brandon
    Nadal, Rosa
    Antonarakis, Emmanuel S.
    PROSTATE, 2017, 77 (01): : 33 - 40